Analysis
Embracing the science of value in health
Murray Krahn, Stirling Bryan, Karen Lee and Peter J. Neumann
CMAJ July 02, 2019 191 (26) E733-E736; DOI: https://doi.org/10.1503/cmaj.181606
Murray Krahn
Toronto Health Economics and Technology Assessment Collaborative (Krahn); Toronto General Hospital Research Institute (Krahn), Toronto, Toronto, Ont.; BC SUPPORT Unit (Bryan), BC Academic Health Science Network, Vancouver, BC; School of Population and Public Health (Bryan), University of British Columbia; Centre for Clinical Epidemiology & Evaluation (Bryan), Vancouver Coastal Health Research Institute, Vancouver, BC; Canadian Agency for Drugs and Technologies in Health (Lee); School of Epidemiology and Public Health (Lee), University of Ottawa, Ottawa, Ont.; Center for the Evaluation of Value and Risk in Health ( Neumann), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Mass.
Stirling Bryan
Toronto Health Economics and Technology Assessment Collaborative (Krahn); Toronto General Hospital Research Institute (Krahn), Toronto, Toronto, Ont.; BC SUPPORT Unit (Bryan), BC Academic Health Science Network, Vancouver, BC; School of Population and Public Health (Bryan), University of British Columbia; Centre for Clinical Epidemiology & Evaluation (Bryan), Vancouver Coastal Health Research Institute, Vancouver, BC; Canadian Agency for Drugs and Technologies in Health (Lee); School of Epidemiology and Public Health (Lee), University of Ottawa, Ottawa, Ont.; Center for the Evaluation of Value and Risk in Health ( Neumann), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Mass.
Karen Lee
Toronto Health Economics and Technology Assessment Collaborative (Krahn); Toronto General Hospital Research Institute (Krahn), Toronto, Toronto, Ont.; BC SUPPORT Unit (Bryan), BC Academic Health Science Network, Vancouver, BC; School of Population and Public Health (Bryan), University of British Columbia; Centre for Clinical Epidemiology & Evaluation (Bryan), Vancouver Coastal Health Research Institute, Vancouver, BC; Canadian Agency for Drugs and Technologies in Health (Lee); School of Epidemiology and Public Health (Lee), University of Ottawa, Ottawa, Ont.; Center for the Evaluation of Value and Risk in Health ( Neumann), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Mass.
Peter J. Neumann
Toronto Health Economics and Technology Assessment Collaborative (Krahn); Toronto General Hospital Research Institute (Krahn), Toronto, Toronto, Ont.; BC SUPPORT Unit (Bryan), BC Academic Health Science Network, Vancouver, BC; School of Population and Public Health (Bryan), University of British Columbia; Centre for Clinical Epidemiology & Evaluation (Bryan), Vancouver Coastal Health Research Institute, Vancouver, BC; Canadian Agency for Drugs and Technologies in Health (Lee); School of Epidemiology and Public Health (Lee), University of Ottawa, Ottawa, Ont.; Center for the Evaluation of Value and Risk in Health ( Neumann), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Mass.

Data supplements
Earn CPD Credits
This article is eligible for 0.5 Mainpro+ credits.
Did you read this article?
Note: The YES link above may not work in certain versions of Internet Explorer 8. If you are having difficulties with this link, please try another browser.
Podcast
Related Articles
- Vijayaraghavan, B. K., Willaert, X., & Cuthbertson, B. H. (2019). Cost-effectiveness analysis should be mandatory in clinical-effectiveness research. CMAJ, 191(41), E1140. Accessed May 23, 2022. https://doi.org/10.1503/cmaj.73298.
In this issue
Article tools
Embracing the science of value in health
Murray Krahn, Stirling Bryan, Karen Lee, Peter J. Neumann
CMAJ Jul 2019, 191 (26) E733-E736; DOI: 10.1503/cmaj.181606
Podcast